How Retail Investors Are Using AI To Make Trades
The transcript explores the evolution of AI in retail investing, moving from AI-powered research tools to autonomous agents that can execute trades on behalf of investors. While some retail investors are building custom AI agents using tools like Claude, current implementations maintain human oversight through approval workflows, with companies cautiously implementing guardrails before AI can act independently on real money.
Summary
The transcript discusses the emerging trend of agentic AI in retail investing, representing a shift from AI that provides investment ideas to AI that can take autonomous action. Currently, retail investors are experimenting with general-purpose AI tools like ChatGPT and Claude to research stocks, analyze markets, and build custom investing agents. One retail investor described using Claude to act as a hedge fund analyst, requesting undervalued stock opportunities and option plays, though he personally reviewed and approved all recommendations before executing trades.
Startups like Podium Markets are building dedicated AI investment agents such as Ivy, which can access user holdings across multiple brokerage accounts and tailor responses based on user risk profiles. However, these current implementations maintain strict human oversight—the AI informs but the human decides, with users required to approve strategies before trading. Online brokerages like Public are building in-house AI agents designed to give retail investors access to more sophisticated strategies while maintaining guardrails that require user approval of workflows before execution.
The transcript suggests three phases of AI investment evolution: phase one involves experimental tinkering with general AI tools connected to brokerage accounts; phase two brings AI agents into portfolios for real-money execution with human oversight; and phase three represents the evolution from execution to advisory capabilities. Some experts believe this progression could lead to AI becoming a comprehensive financial operating system that optimizes an investor's entire financial life, not just investments, operating 24/7 across multiple financial decisions.
However, significant challenges remain. One developer who built an automated trading experiment with $200 lost money consistently, illustrating the risks of over-relying on AI agents. A major challenge is translating vague human goals into precise investing instructions—for example, 'grow my portfolio aggressively' requires clarification on whether that means increased volatility, concentrated holdings, or options strategies. Regulatory concerns are also paramount, as firms remain responsible for ensuring agents behave as modeled and maintain customer best interests, making them cautious about granting AI unlimited authority.
Key Insights
- The industry is moving from AI that gives investors research ideas to AI that can take autonomous action on their behalf, representing a fundamental shift in how AI is deployed in investing
- A retail investor successfully used Claude to generate undervalued stock recommendations and option trades by prompting it to act as a hedge fund analyst, though he maintained final decision authority on all trades
- Current AI investment platforms like Ivy maintain a model where 'AI informs, but the human decides,' requiring users to approve strategies before trading rather than granting autonomous execution authority
- An experienced developer who built an automated trading agent with $200 consistently lost money, suggesting that current AI agents may not be reliable for autonomous trading without professional oversight
- A critical challenge in AI investing is translating vague human goals like 'grow my portfolio aggressively' into precise technical instructions, which different AI agents might interpret in fundamentally different ways
Topics
Transcript
[0:00] Imagine waking up tomorrow morning and discovering that an AI agent has been managing your investments overnight. While you were sleeping, an AI agent monitored earnings reports, scanned breaking news, harvested tax losses, and adjusted your exposure to market volatility. And you didn't manually place a single trade. That future may be closer than many investors think very soon. Here we're going to be moving to what I would call 2.0, where firms are actually creating agentic solutions within their own organization or within their [0:32] own app, where a customer can come into that app, give their life circumstances: I'm Devin. I'm 45. I have three children. Here's my risk tolerance. Here are my goals. Here are the…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
What Do Banks Risk Working With Trump’s $858 Million Investment Portfolio?
CNBC investigation reveals that JPMorgan Chase, Charles Schwab, UBS, and Stephens Incorporated manage at least four of President Trump's eight investment accounts, which collectively held $858 million in 2025 and generated over 21,000 trades. Financial institutions face significant compliance and reputational risks from managing a sitting president's wealth, while gaining valuable access to presidential influence as compensation.
Why Fed Chairman Warsh Says 'Inflation Is A Choice'
Fed Chairman Kevin Warsh argues that inflation is fundamentally a choice and responsibility of the Federal Reserve, not an inevitable economic force. The transcript explores how this perspective shapes Fed policy communication and decision-making, while acknowledging the complexity of distinguishing between supply shocks and demand-driven inflation.
Why Europe is betting big on drones
Europe is dramatically increasing investment in military drone technology and AI-powered autonomous systems, driven by lessons learned from the Ukraine war. Recent developments include NATO's drone initiative, UK funding pledges, German orders for Ukraine, and major defense tech valuations, signaling that drones and their supporting technologies are now central to modern military strategy.
This new Medicare program offers obesity drugs for $50 a month. Here's what you need to know
Medicare has launched a new pilot program called Bridge that allows eligible seniors to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month copays, starting this week. This represents a major policy shift as Medicare has historically excluded obesity medications from coverage, and could potentially reach millions of beneficiaries and expand access to drugs that normally cost hundreds of dollars monthly.
Inside the rise and fall of Kohl's
Kohl's, once a beloved department store chain, experienced a dramatic decline from its 2018 peak of $82 per share to under $20, losing 70% of its value over five years. New CEO Michael Bender attributes the decline to the company losing its identity and core customer focus, and is now implementing a turnaround strategy centered on returning to the company's original value-oriented approach.